At Kanyos, we are focused on translating the antigen-specific immune tolerance technology developed at Anokion to develop targeted treatments for celiac disease and type-1 diabetes.
Celiac disease is an autoimmune-like disorder where the body’s immune system specifically reacts against wheat-derived proteins in the gut during digestion, a process that results in immune-mediated destruction of the nutrient-absorbing cells in the intestine. By engineering these proteins using the Anokion technology, Kanyos is developing a targeted treatment option for patients, which will specifically inhibit only the immune cells inducing damage to the intestine, while leaving the other immune cells unchanged and capable of fulfilling their important functions.
Type-1 diabetes is an autoimmune disease where the body’s immune system erroneously recognizes self proteins from the pancreas as foreign, and mounts a destructive attack against the insulin-producing cells of the pancreas. In harnessing the tolerogenic potential of endogenous erythrocytes (red blood cells), Kanyos aims to develop a first-in-class therapy capable of re-training the immune system to specifically recognize the pancreas as “self,” and thus selectively inhibit only the immune cells responsible for the disease.